Comparative Pharmacology
Head-to-head clinical analysis: NICODERM CQ versus NICOTROL.
Head-to-head clinical analysis: NICODERM CQ versus NICOTROL.
NICODERM CQ vs NICOTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nicotine is a nicotinic cholinergic receptor agonist that stimulates ganglia and the CNS, leading to release of catecholamines and other neurotransmitters. In smoking cessation, it acts as a replacement therapy to reduce withdrawal symptoms and cravings by binding to nicotinic acetylcholine receptors in the brain.
Nicotine is a nicotinic acetylcholine receptor agonist. It binds to and activates nicotinic acetylcholine receptors in the brain, leading to dopamine release and other neurotransmitter effects that mediate nicotine dependence and withdrawal symptoms.
Apply one 7 mg/24 hour, 14 mg/24 hour, or 21 mg/24 hour transdermal patch to non-hairy, clean, dry skin on the upper body or upper outer arm once daily. Initial dose based on smoking status: patients smoking >10 cigarettes/day: 21 mg/24 hours; patients smoking ≤10 cigarettes/day: 14 mg/24 hours. Titrate based on withdrawal symptoms.
Inhalation: 1 cartridge (4 mg) inhaled as needed for craving relief, up to 16 cartridges per day; typical initial dose: 4-8 cartridges per day, with weaning over 12 weeks.
None Documented
None Documented
Terminal elimination half-life ~2 hours (range 1-4 h) after transdermal patch removal; clinically, levels decline rapidly, requiring scheduled reapplication.
2 hours (range 1-4 h). Shorter in smokers due to induction of metabolism; prolonged in renal impairment.
Primarily renal; about 10-20% excreted unchanged, remainder as metabolites (cotinine and nicotine-N'-oxide). Total clearance ~1.2 L/min. Biliary/fecal excretion negligible (<5%).
Primarily renal (10-20% unchanged; 80-90% as metabolites, mainly cotinine and nicotine-N'-oxide). Biliary/fecal excretion accounts for <10%.
Category C
Category C
Smoking cessation aid
Smoking cessation aid